Notice of Closed Meeting, 3406-3407 [2024-00826]
Download as PDF
<![CDATA[
3406
Federal Register / Vol. 89, No. 12 / Thursday, January 18, 2024 / Notices
khammond on DSKJM1Z7X2PROD with NOTICES
Summary of Proposed Order With
Respondent
The Proposed Order contains
injunctive relief designed to prevent
Respondents from engaging in the same
or similar acts or practices in the future.
Part I prohibits Respondents from
misrepresenting the extent to which (1)
it collects, maintains, uses, discloses,
deletes any covered information, and (2)
the location data that Respondents
collect, use, maintain, or disclose is
deidentified.
Part II prohibits Respondents from
selling, licensing, transferring, sharing,
disclosing, or using sensitive location
data in any products or services.
Sensitive locations are defined as those
locations in the United States associated
with (1) medical facilities (e.g., family
planning centers, general medical and
surgical hospitals, offices of physicians,
offices of mental health physicians and
practitioners, residential mental health
and substance abuse facilities,
outpatient mental health and substance
abuse centers, outpatient care centers,
psychiatric and substance abuse
hospitals, and specialty hospitals); (2)
religious organizations; (3) correctional
facilities; (4) labor union offices; (5)
locations of entities held out to the
public as predominantly providing
education or childcare services to
minors; (6) associations held out to the
public as predominantly providing
services based on racial or ethnic origin;
or (7) locations held out to the public as
providing temporary shelter or social
services to homeless people, survivors
of domestic violence, refugees, or
immigrants.
Part III requires that Respondents
implement and maintain a sensitive
location data Program to develop a
comprehensive list of sensitive locations
and to prevent the use, sale, license,
transfer, or disclosure of sensitive
location data.
Part IV requires that Respondents
establish and implement policies,
procedures, and technical measures
designed to prevent recipients of
Respondents’ location data from
associating consumers with locations
providing services to LGBTQ+
individuals, locations of public
gatherings of individuals during social
demonstrations, marches, or protests, or
using location data to determine the
identity or location of an individual’s
home.
Part V requires Respondents to notify
the Commission any time it determines
that a third party shared Respondents’
Location Data, in violation of a
contractual requirement between
Respondents and the third party.
VerDate Sep<11>2014
17:32 Jan 17, 2024
Jkt 262001
Part VI requires that Respondents
must not collect, use, maintain, and
disclose location data (1) when
consumers have opted-out, or otherwise
declined targeted advertising, (2)
without a record documenting the
consumer’s consent obtained prior to
the collection of location data, and (3)
in connection with Respondents’ apps
unless consumers receive a clear and
conspicuous quarterly reminder about
location data being collected.
Part VII requires that Respondents
implement a supplier assessment
program designed to ensure that
consumers have provided consent for
the collection and use of location data
obtained by Respondents. Under this
program, Respondents must conduct
initial assessments of all their data
suppliers within 30 days of entering
into a data sharing agreement, or within
30 days of the initial date of data
collection. The program also requires
that Respondents confirm that
consumers provide consent and create
and maintain records of suppliers’
assessment responses. Finally,
Respondents must cease from using,
selling, or disclosing location data for
which consumers have not provided
consent.
Part VIII requires that Respondents
provide a clear and conspicuous means
for consumers to request the identity of
any entity, business, or individual to
whom their location data has been sold,
transferred, licensed, or otherwise
disclosed or a method to delete the
consumers’ location data from the
databases of Respondents’ customers.
Respondents must also provide written
confirmation to consumers that the
deletion requests have been sent to
Respondents’ customers.
Part IX requires that Respondents
provide a simple, easily-located means
for consumers to withdraw any consent
provided and Part X requires that
Respondents cease collecting location
data within 15 days after Respondents
receive notice that the consumer
withdraws their consent.
Part XI also requires that Respondents
provide a simple, easily-located means
for consumers to request that
Respondents delete location data that
Respondents previously collected and to
delete the location data within 30 days
of receipt of such request unless a
shorter period for deletion is required
by law.
Part XII requires that Respondents (1)
document and adhere to a retention
schedule for the covered information it
collects from consumers, including the
purposes for which it collects such
information, the specific business
needs, and an established timeframe for
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
its deletion, and (2) prior to collecting
or using new type of information related
to consumers that was not previously
collected, and is not described in its
retention schedule, Respondents must
update its retention schedule.
Part XIII requires that Respondents
delete or destroy all historic location
data and all data products. Respondents
have the option to retain historic
location data if it has obtained
affirmative express consent or it ensures
that the historic location data is
deidentified or rendered non-sensitive.
Respondents must inform all customers
that received location data from
Respondents within 3 years prior to the
issuance date of this Order, of the
Commission’s position that such data
should be deleted, deidentified, or
rendered non-sensitive.
Part XIV requires Respondents to
establish and implement, and thereafter
maintain, a comprehensive privacy
program that protects the privacy of
consumers’ personal information.
Parts XV–XVIII are reporting and
compliance provisions, which include
recordkeeping requirements and
provisions requiring Respondent to
provide information or documents
necessary for the Commission to
monitor compliance.
Part XIX states that the Proposed
Order will remain in effect for 20 years,
with certain exceptions.
The purpose of this analysis is to
facilitate public comment on the
Proposed Order, and it is not intended
to constitute an official interpretation of
the complaint or Proposed Order, or to
modify the Proposed Order’s terms in
any way.
By direction of the Commission.
April J. Tabor,
Secretary.
[FR Doc. 2024–00928 Filed 1–17–24; 8:45 am]
BILLING CODE 6750–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Pursuant to 5 U.S.C. 1009(d), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, CDC, pursuant to Public Law
92–463. The grant applications and the
E:\FR\FM\18JAN1.SGM
18JAN1
Federal Register / Vol. 89, No. 12 / Thursday, January 18, 2024 / Notices
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
RFA–IP–24–045, Network of
Community Cohorts for Monitoring
Changes in Respiratory Virus
Epidemiology (Pandemic Preparedness
Cohorts).
Dates: April 25–26, 2024.
Times: 10 a.m.–5 p.m., EDT.
Place: Videoconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Gregory Anderson, MS, M.P.H,
Scientific Review Officer, National
Center for HIV, Viral Hepatitis, STD,
and TB Prevention, Centers for Disease
Control and Prevention, 1600 Clifton
Road NE, Mailstop H24–6, Atlanta,
Georgia 30329–4027. Telephone: (404)
718–8833; Email: GAnderson@cdc.gov.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2024–00826 Filed 1–17–24; 8:45 am]
BILLING CODE 4163–18–P
comment on CMS’ intention to collect
information from the public. Under the
Paperwork Reduction Act of 1995
(PRA), federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension or reinstatement of an existing
collection of information, and to allow
a second opportunity for public
comment on the notice. Interested
persons are invited to send comments
regarding the burden estimate or any
other aspect of this collection of
information, including the necessity and
utility of the proposed information
collection for the proper performance of
the agency’s functions, the accuracy of
the estimated burden, ways to enhance
the quality, utility, and clarity of the
information to be collected, and the use
of automated collection techniques or
other forms of information technology to
minimize the information collection
burden.
Comments on the collection(s) of
information must be received by the
OMB desk officer by February 20, 2024.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
To obtain copies of a supporting
statement and any related forms for the
proposed collection(s) summarized in
this notice, please access the CMS PRA
website by copying and pasting the
following web address into your web
browser: https://www.cms.gov/
Regulations-and-Guidance/Legislation/
PaperworkReductionActof1995/PRAListing.
DATES:
FOR FURTHER INFORMATION CONTACT:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifier: CMS–10346]
khammond on DSKJM1Z7X2PROD with NOTICES
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Centers for Medicare &
Medicaid Services, Health and Human
Services (HHS).
ACTION: Notice.
AGENCY:
The Centers for Medicare &
Medicaid Services (CMS) is announcing
an opportunity for the public to
SUMMARY:
VerDate Sep<11>2014
17:32 Jan 17, 2024
Jkt 262001
William Parham at (410) 786–4669.
Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. The term ‘‘collection of
information’’ is defined in 44 U.S.C.
3502(3) and 5 CFR 1320.3(c) and
includes agency requests or
requirements that members of the public
submit reports, keep records, or provide
information to a third party. Section
3506(c)(2)(A) of the PRA (44 U.S.C.
3506(c)(2)(A)) requires federal agencies
to publish a 30-day notice in the
Federal Register concerning each
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
3407
proposed collection of information,
including each proposed extension or
reinstatement of an existing collection
of information, before submitting the
collection to OMB for approval. To
comply with this requirement, CMS is
publishing this notice that summarizes
the following proposed collection(s) of
information for public comment:
1. Type of Information Collection
Request: Extension without change of a
currently approved collection; Title of
Information Collection: Quality Bonus
Payment Appeals; Use: Section 1853(o)
of the Act requires CMS to make QBPs
to MA organizations that achieve
performance rating scores of at least 4
stars under a five-star rating system.
While CMS has applied a Star Rating
system to MA organizations for a
number of years, prior to the QBP
program these Star Ratings were used
only to provide additional information
for beneficiaries to consider in making
their Part C and D plan elections.
Beginning in 2012, the Star Ratings CMS
assigns for purposes of QBPs directly
affected the monthly payment amount
MA organizations receive from CMS
under their contracts. Additionally,
section 1854(b)(1)(C)(v) of the Act, as
added by the Affordable Care Act, also
requires CMS to change the share of
savings that MA organizations must
provide to enrollees as the beneficiary
rebate specified at § 422.266(a) based on
the level of a sponsor’s Star Rating for
quality performance.
The information collected on the
Request for Reconsideration form from
MA organizations is considered by the
reconsideration official and potentially
the hearing officer to review CMS’s
determination of the organization’s
eligibility for a QBP. The form asks MA
organizations to select the Star Ratings
measure(s) they believe was
miscalculated or used incorrect data and
describe what they believe is the issue.
Under § 422.260(c)(3)(ii) these are the
only bases for appeals. In conducting
the reconsideration, the reconsideration
official will review the QBP
determination, the evidence and
findings upon which it was based, and
any other written evidence submitted by
the organization with their Request for
Reconsideration or by CMS before the
reconsideration determination is made.
Form Number: CMS–10346 (OMB
Control Number 0938–1129; Frequency:
Yearly; Affected Public: Private Sector;
Number of Respondents: 20; Total
Annual Responses: 20; Total Annual
Hours: 160. (For policy questions
regarding this collection contact, Sarah
Gaillot at 410–786–4637.)
E:\FR\FM\18JAN1.SGM
18JAN1
]]>Agencies
[Federal Register Volume 89, Number 12 (Thursday, January 18, 2024)]
[Notices]
[Pages 3406-3407]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-00826]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Closed Meeting
Pursuant to 5 U.S.C. 1009(d), notice is hereby given of the
following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended, and the Determination of the Director, Office of
Strategic Business Initiatives, Office of the Chief Operating Officer,
CDC, pursuant to Public Law 92-463. The grant applications and the
[[Page 3407]]
discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)--RFA-IP-24-045, Network of
Community Cohorts for Monitoring Changes in Respiratory Virus
Epidemiology (Pandemic Preparedness Cohorts).
Dates: April 25-26, 2024.
Times: 10 a.m.-5 p.m., EDT.
Place: Videoconference.
Agenda: To review and evaluate grant applications.
For Further Information Contact: Gregory Anderson, MS, M.P.H,
Scientific Review Officer, National Center for HIV, Viral Hepatitis,
STD, and TB Prevention, Centers for Disease Control and Prevention,
1600 Clifton Road NE, Mailstop H24-6, Atlanta, Georgia 30329-4027.
Telephone: (404) 718-8833; Email: [email protected].
The Director, Office of Strategic Business Initiatives, Office of
the Chief Operating Officer, Centers for Disease Control and
Prevention, has been delegated the authority to sign Federal Register
notices pertaining to announcements of meetings and other committee
management activities, for both the Centers for Disease Control and
Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2024-00826 Filed 1-17-24; 8:45 am]
BILLING CODE 4163-18-P
